Cysteine- and glycine-rich protein 1 predicts prognosis and therapy response in patients with acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2024 at "Clinical and Experimental Medicine"
DOI: 10.1007/s10238-023-01269-w
Abstract: Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. The current risk stratification system is essential but remains insufficient to select the best schedules. Cysteine-rich protein 1 ( CSRP1 ) is a… read more here.
Keywords: acute myeloid; csrp1; protein; rich protein ... See more keywords